Caricamento...
HOUT-22. PATTERN OF BEVACIZUMAB USE IN PATIENTS WITH GLIOBLASTOMA AT NATIONAL CANCER INSTITUTE-DESIGNATED CANCER CENTERS IN 2017
BACKGROUND: Bevacizumab (BEV) received accelerated FDA approval in 2009 for the treatment of recurrent glioblastoma (rGBM). Three prospective randomized controlled phase III studies (2 in newly-diagnosed, one in rGBM) failed to show an overall survival benefit of BEV in the treatment of GBM. We aime...
Salvato in:
| Pubblicato in: | Neuro Oncol |
|---|---|
| Autori principali: | , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Oxford University Press
2017
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5692508/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.452 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|